Cytokinetics (CYTK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 129,843 | 122,518 | 225,467 | 74,940 | 73,680 |
| Marketable Securities | 688,707 | 759,703 | 737,068 | 783,195 | 864,538 |
| Receivables | 6,827 | 17,764 | 1,808 | 8,410 | 2,012 |
| Inventories | 154 | N/A | N/A | N/A | N/A |
| TOTAL | $839,465 | $916,975 | $977,349 | $886,542 | $956,053 |
| Non-Current Assets | |||||
| PPE Net | 82,438 | 79,194 | 76,001 | 70,219 | 67,175 |
| Investments And Advances | 254,719 | 335,048 | 288,817 | 178,201 | 150,687 |
| Other Non-Current Assets | 96,856 | 93,320 | 94,390 | 90,673 | 90,136 |
| TOTAL | $434,013 | $507,562 | $459,208 | $339,093 | $307,998 |
| Total Assets | $1,273,478 | $1,424,537 | $1,436,557 | $1,225,635 | $1,264,051 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 44,808 | 41,181 | 37,927 | 14,400 | 12,960 |
| Accounts payable and accrued liabilities | 24,709 | 22,337 | 22,084 | 16,228 | 13,942 |
| Accrued Expenses | 68,863 | 83,278 | 61,633 | 52,315 | 43,358 |
| Other current liabilities | 38,192 | 34,933 | 18,888 | 27,192 | 17,522 |
| TOTAL | $199,185 | $202,452 | $142,144 | $131,064 | $159,726 |
| Non-Current Liabilities | |||||
| Long Term Debt | 247,209 | 246,384 | 158,747 | 159,058 | 92,025 |
| Deferred Revenues | 1,653 | 1,612 | 1,612 | 1,344 | 52,370 |
| Other Non-Current Liabilities | 1,653,652 | 1,635,326 | 1,656,789 | 1,304,233 | 1,278,713 |
| TOTAL | $1,900,861 | $1,881,710 | $1,815,536 | $1,463,291 | $1,370,738 |
| Total Liabilities | $2,100,046 | $2,084,162 | $1,957,680 | $1,594,355 | $1,530,464 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 124,433 | 123,163 | 122,265 | 119,657 | 119,427 |
| Common Shares | 124 | 123 | 122 | 119 | 119 |
| Retained earnings | -3,692,750 | -3,486,719 | -3,303,688 | -2,997,510 | -2,863,140 |
| Other shareholders' equity | -1,612 | 630 | 34 | -158 | 1,545 |
| TOTAL | $-826,568 | $-659,625 | $-521,123 | $-368,720 | $-266,413 |
| Total Liabilities And Equity | $1,273,478 | $1,424,537 | $1,436,557 | $1,225,635 | $1,264,051 |